Nearly 7 million Americans are living with Alzheimer’s, and even more may be in the early, undiagnosed stages of this devastating disease. But a new era of earlier detection and diagnosis offers hope—one where patients can be identified sooner, given more options earlier, and be better equipped to potentially slow disease progression.
Join Eli Lilly & Company in Atlanta for an event that will bring together legislators, health officials, physicians, employers, and patient advocates to explore the barriers, breakthroughs, and policies shaping Alzheimer’s detection.
Georgia is leveraging its cutting-edge research institutions and advancements in precision medicine to make meaningful strides for the over 180,000 residents living with Alzheimer’s disease. To build on this momentum, we are gathering physicians, policymakers, and advocates to discuss innovations in diagnosis and new pathways for care.
Don’t miss this critical conversation on the future of Alzheimer’s care.
If you are a licensed US Prescriber or a Health Care Provider licensed in a state with laws requiring payment disclosures, please be aware of Lilly’s transparency reporting requirements as a result of enacted federal and state legislation.
As a result of enacted state and federal legislation, if you are a prescriber or other licensed healthcare professional with an active license from MA, MN, NJ and/or VT, a Veterans Affairs employee, and/or a state or federal government employee, you may be restricted from accepting industry-provided food/beverage. Please consult your state or federal regulations or ethics laws.
